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SUMMARY
Introduction Alpha-1-antitrypsin deficiency (AATD) is a relatively rare and clinically very heterogeneous 
autosomal recessive disorder.
Objective Presentation of clinical characteristics of AATD in the first months after birth, as well as the 
significance of testing brothers and sisters for its presence.
Methods Objectives of the study were analyzed on a sample of eight children (four male and four female, 
aged 63 months (mean14.81±23.96 months; range 1-63 months) with AATD confirmed based on its low 
serum value and pathological phenotype.
Results Of the total of eight patients, six manifested cholestasis syndrome (three male and three fe-
male, mean age 2.25±1.37 months; range 1-4.5 months), while two patients, a 3.5-year-old girl and a 
5.25-year-old boy, were without symptoms and clinical-laboratory signs of the disease, disclosed during 
family testing. Serum alpha-1-antitrypsin level rated 0.30-0.66 g/L (0.37±0.12), among which seven were 
with ZZ phenotype 0.30-0.39 (0.33±0.04), and in a boy with FZ the phenotype was disclosed on family 
screening, 0.66 g/L. In the group of patients with cholestasis syndrome (serum GTT 444.80±203.15 U/L; 
range 201-676 U/L), three had mild to moderate hepatomegaly, one had longitudinal growth delay (<P3; 
-10.50%) and two had icterus with conjugated hyperbilirubinemia (92 and 109 μmol/L) and prolonged 
prothrombin time (PT 14.8 and 17 sec). All children with cholestasis syndrome also had hypertransami-
nasemia (ALT 80.83±33 U/L; range 37-124 U/L and AST 116.67±62.82 U/L; range 58-230 U/L).
Conclusion Cholestasis syndrome represents a basic manifestation of AATD in the first months after 
birth, while early testing of brothers and sisters enables early disclosure and adequate treatment of the 
subclinical forms of the disease.
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INTRODUCTION
Alpha-1-antitrypsin deficiency (AATD) rep-
resents a relatively rare and clinically a rather 
heterogeneous autosomal recessive disorder of 
serpinopathy group [1, 2, 3]. It is present in 
all regions worldwide, but most often in the 
population derived from the European an-
cestry (1:2000-6700), particularly those from 
Northern Europe (1:1600) [1-5]. The basis of 
the disease forms a defect in the hepatocyte 
expression of alpha-1-antitrypsin followed by 
damage of the liver and/or lungs, and rarely of 
other body structures [1, 2, 3]. Liver changes 
develop due to intra-hepatocytic retention and 
alpha-1-antitrypsin polymerization, while pul-
monary and other are the result of the lack of 
its protective effect, as well as its regulatory 
participation in the process of inflammation 
and tissue repair [1, 6, 7, 8].
Viewed from the clinical aspect, AATD can 
be asymptomatic or long-lastingly and even 
permanently symptomatic [1, 2, 3, 9]. The type 
of its expression depends on the genotype, but 
also of numerous exogenous factors, such as 
various infective, toxic and other damages of 
the liver and/or lungs [1, 2, 3, 9]. Symptomatic 
liver damage can be seen in all ages, also in-
cluding in first weeks after birth, while pul-
monary damage occurs in persons aged over 
40-50 years, but very rarely in puberty [2, 3]. 
Other manifestations of the disease, such as 
membranoproliferative glomerulitis, necrotiz-
ing panniculitis, recurrent vasculitis, vascular 
aneurysms and other are much rarer or excep-
tionally rare 1, 2, 3, 6, 7].
OBJECTIvE
The objective of the study was to present clini-
cal characteristics of AATD in the first months 
after birth, as well as the significance of testing 
brothers and sisters for its presence.
METHODS
The studied sample was composed of eight 
children (four male and four female) aged 
1-63 (14.81±23.96) months. Six patients had 
a symptomatic form of the disease, while two 
were disclosed during family testing. The diag-
nosis of AATD is based on the determination   
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of its low serum level (<0.8 g/L, below 50% of normal) 
and phenotypic analysis [1, 10]. With the aim of adequate 
interpretation of alpha-1-antitrypsin concentration in se-
rum of all patients, based on relevant clinical-laboratory 
parameters, also including normal values of C-reactive 
protein (CRP) and erythrocyte sedimentation rate (ESR), 
we excluded possible infective and other inflammatory 
processes. To identify Pi alleles (alfa-1-antitripsin pheno-
typisation), isoelectric focusing was carried out (pH range 
4.2-4.9) according to the method by Kishimoto et al. [11].
Beside a detailed anamnesis and clinical examina-
tion, also including comparison of body length (BL) and 
weight (BW) with referent values, serum levels of total 
and conjugated bilirubin, γ-glutamyltransferase (GGT), 
alkaline phosphatase (ALP), prothrombin time (PT), 
partial thromboplastin time (PTT), total cholesterol, 
alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), total protein, albumin, glucose, calcium and 
phosphorus were determined. All laboratory values were 
compared with referent values for the matched age [10]. 
Also, all patients were screened by ultrasound examina-
tion of the abdomen and complete urine analysis testing. 
A 2.5-months old patient underwent intra-operative cho-
liangiography with liver biopsy, as his illness history from 
the previous hospital already contained information on 
normal alpha-1-antitrypsin in serum but without data on 
a parallel intercurrent bacterial infection about which we 
were informed later. Having in mind a wide differential 
diagnosis of cholestasis syndrome at such an early phase 
of life as well as due to a possible comorbidity in all pa-
tients with the clinically manifest form of AATD, in the 
initial phase of the study metabolic screening of urine and 
serological test for Toxoplasma gondii, rubella, cytomega-
lovirus and herpes simplex virus were done in two and 
sweat test in three patients. Having in mind the fact that 
all mothers were HBs negative and that all children had 
been vaccinated against hepatitis B, studies were not done 
in this direction.
RESULTS
Of the total of eight patients with AATD, six manifested 
cholestasis syndrome (three male and three female, mean 
age 2.25±1,37 months; range 1-4.5 months), while two, 
a 3.5-year-old girl and a 5.25-year-old boy, were without 
symptoms and clinical-laboratory signs of the disease dis-
closed during family testing. Serum alpha-1-antitrypsin 
level rated 0.30-0.66 g/L (0.37±0.12), among which seven 
were with ZZ phenotype 0.30-0.39 (0.33±0.04), and in 
the boy with FZ phenotype disclosed on family screening 
0.66 g/L. In the group of patients with cholestasis syn-
drome (serum GTT 444.80±203.15 U/L; range 201-676 
U/L), three had mild to moderate hepatomegaly; one 
longitudinal growth delay (<P3; -10.50%) and two had 
icterus with conjugated hyperbilirubinemia (92 and 109 
μmol/L) with prolonged PT (14.8 and 17 sec). All chil-
dren with cholestasis syndrome also had hypertransami-
nasemia (ALT 80.83±33 U/L; range 37-124 U/L and AST 
116.67±62.82 U/L; range 58-230 U/L). Liver tissue histo-
logical findings in a 2.5 months old infant with the PiZZ 
fenotype and serum concentration of alpha-1-antitrypsin 
of 0.35 g/L corresponded to neonatal hepatitis, but without 
evident intracellular PAS-positive globules. Either pulmo-
nary manifestations of the disease or any other comorbid 
conditions with similar clinical-laboratory presentations 
were not registered in any of the patients.
In further course, i.e. in the children aged 1.25-6.75 
years (3,52±1.88), all patients were of good general condi-
tion, normal nutritional, growth and developmental status, 
as well as with absence of any disorders that would point at 
the presence of AATD. In five of six children, cholestasis 
was followed by normalization; in two under treatment 
with ursodeoxycholic acid and in three spontaneously. 
Only in the oldest patient, the 7-year-old boy, we regis-
tered persistent cholestasis syndrome (serum GGT 212 
U/L; normal <55 U/L) with hypercholesterolemia (6.48 
mmol/L; normal <6.22 mmol/L), hypertransaminasemia 
(ALT 138 U/L; normal <49 U/L and AST 108 U/L; normal 
<36 U/L) and ultrasonographic signs of mild non-homog-
enous hepatomegaly. Other laboratory analyses and spleen 
size were within normal limits.
DISCUSSION
Alpha-1-antitrypsin is a glycoprotein, with 52 kDa mo-
lecular weight, from the superfamily of serine protease 
inhibitors (serpin), with a special affinity to granulocytic 
elastases [1, 2]. It is primarily produced in hepatocytes 
(~80%), and to a lesser part in macrophages, monocytes, 
broncho-alveolar epithelium, colonocytes and endocrine 
pancreas cells from where it is secreted, under the influ-
ence of proinflammatory cytokines, into the blood circu-
lation where it forms 80% of α1-globulins fraction [3, 12, 
13, 14]. It belongs to the first phase reactants of inflam-
mation with the circulation half-life of 4-5 days and the 
basic role to suppress autodestructive, i.e. additional tissue 
damage, by neutralizing granulocytic elastase, primarily 
of the lungs during various infective and non-infective 
inflammatory processes [2, 3, 13, 14]. Beside protective-
immunomodulatory effect, alfa-1-antitrypsin is significant 
as the tissue reparation inductor [2, 3, 15].
Alfa-1-antitripsyn encodes SERPINA 1 gene located 
on the long arm of chromosome 14 (14q31–32.3) [1, 2, 
3]. Up-to-now over 120 variations of this gene have been 
discovered, among which one third is in homozygous con-
dition or inter-individual variant combination followed by 
a deficit or dysfunction of alpha-1-antitrypsin [1, 9]. The 
most frequent normal allele present in 95% of the Euro-
pean population is M, while defect S and Z alleles, which 
are in homozygous condition (PiZZ) are responsible for 
95% of clinically manifest forms of the disease [1, 15, 16]. 
F, Null, Siiyama, Mmalton, Mprocida, Mheerlen, Mmin-
eral springs, Psalt-like, Mnichinan, Pduarte, Wbethesda 
Zaugsberg, Zbristol, Pittsburgh and other pathological 
mutations are much rarer or exceptionally rare [14, 15, 
17-22].     
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Pathogenetic basis of the most frequent form of the de-
fect creates a defect in the expression of alpfa-1-antitrypsin 
followed by destructive damage of the liver and/or lungs 
[1, 2, 3, 14]. Liver lesion develops due to intrahepatocytic 
retention and polymerization of the defective alpha-1-anti-
trypsin, and of the lungs as the result of lack, not only of its 
protective effect, but also of regulatory participation in the 
process of inflammation and tissue reparation [1, 6, 7, 8]. 
The accumulation of defective alpha-1-antitripsin in the 
liver, most expressed in periportal and paraseptal hepa-
tocytes, is characteristic of ZZ as well as the homozygous 
and heterozygous combination of Mmalton, Pduarte and 
Siiyama genotypes [1, 2, 14]. This pathological process, 
mediated by proinflammatory cytokines, induces all in-
flammatory diseases, either intra- or extrahepatic, par-
ticularly if followed by high fever [2, 14, 17]. In all other 
mutations, such as S, F, Psalt like, Null and Pitsburgh, 
hepatocytic retention alpha-1-antitrypsin is absent, so 
that only extrahepatic manifestations of the disease are 
expressed; in the first case due to its short half-life, in the 
second and third due to poor activity, in the fourth due 
to a complete blockage of synthesis, and in the fifth due 
to antithrombotic effect [1, 3, 14, 20-23]. Besides, there is 
also the presence of various combinations of pathological 
alleles, such as SZ, SF and others, and therefore, in ac-
cordance with their defectiveness, most variable clinical 
manifestations [1, 2, 9, 14, 18].
Clinical and phenotypic characteristics of AATD in 
our patients were characteristic of childhood period [12, 
14]. Six of eight patients with AATD, all six with the PiZZ 
phynotype, manifested cholestasis syndrome, while two, 
without clinical-laboratory indicators of the disease, and 
PiZZ and PiZF phenotype, were disclosed during fam-
ily testing [2, 24]. All patients with cholestasis syndrome 
were in early infancy (mean age 2.25±1.37 months; range 
1-4.5 months) and with the PiZZ phenotype, while the re-
maining two were aged 3.5 and 5.25 years, and with the 
PiZZ and PiZF phenotype. Except for cholestasis syn-
drome, other manifestations of the disease were not reg-
istered. Pathohistological analysis of liver tissue in a 2.5 
month old infant, with the PiZZ phenotype and serum con-
centration of alpha-1-antitrypsin of 0.35 g/L, did not show 
the presence of PAS-positive globules, which confirms the 
fact that such a finding, due to the short duration of the dis-
ease within the first three months, is not expected anyway 
[25, 26]. Although liver damage can be exceptionally severe 
in 1-2% of patients, most often it has a slowly progressive 
character so that juvenile cirrhosis develops only in 15% 
of cases [2, 14, 25]. Our patients, who have been under 
follow-up from 1.25-6.75 (3.52±1.88) years, for the time 
being have not either disorder of growth and development 
or symptoms that would point at the presence of AATD. 
Only one of them, a boy now aged seven years, manifests 
persistent cholestasis syndrome with mild hepatomegaly 
and ultrasound signs of initial liver cirrhosis.
CONCLUSION
AATD represents a highly heterogeneous clinical entity de-
pendent of the type of genotype, age, as well as numerous 
exogenous factors. Genetic basis of the disease with early 
expressions forms of ZZ genotype, and clinical cholesta-
sis syndrome. Besides, the essential characteristic of the 
disease is that clinical-laboratory indicators of cholesta-
sis, present in the first weeks after birth, most often get 
lost at later age. Having in mind the mode of inheritance, 
as well as the progressive character of the disease, testing 
the first degree relatives for AATD enables disclosure of 
subclinical forms of the disease, and therefore enable the 
implementation of adequate measures aimed at slowing-
down its progression.
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КРАТАК САДРЖАЈ
Увод Не  до  ста  так ал  фа-1 ан  ти  трип  си  на (AATD) је ре  ла  тив  но 
ре  дак и кли  нич  ки ве  о  ма хе  те  ро  ген ауто  зом  но ре  це  сив  ни 
по  ре  ме  ћај.
Циљ ра  да Циљ ра  да је био да се при  ка  жу кли  нич  ке од  ли  ке 
AATD у пр  вим ме  се  ци  ма по ро  ђе  њу, као и зна  чај те  сти  ра  ња 
бра  ће и се  ста  ра на овај по  ре  ме  ћај.
Ме  то  де ра  да Ис  пи  та  но је осмо  ро де  це (че  ти  ри де  ча  ка 
и че  ти  ри де  вој  чи  це) уз  ра  ста од ме  сец да  на до 63 ме  се  ца 
(про  сеч  но 14,81±23,96 ме  се  ци) са AATD, ко  ји је до  ка  зан на 
осно  ву ни  ске вред  но  сти ал  фа-1 ан  ти  трип  си  на у се  ру  му и 
па  то  ло  шког фе  но  ти  па.
Ре  зул  та  ти Код ше  сто  ро де  це (три де  ча  ка и три де  вој  чи  це) 
уз  ра  ста од ме  сец да  на до че  ти  ри и по ме  се  ца (про  сеч  но 
2,25±1,37 ме  се  ци) ис  по  љио се хо  ле  ста  зни син  дром, док су 
два де  те  та (тро  и  по  го  ди  шња де  вој  чи  ца и де  чак уз  ра  ста од 
5,25 го  ди  на) би  ла без симп  то  ма и кли  нич  ко-ла  бо  ра  то  риј-
ских зна  ко  ва AATD, али је бо  лест от  кри  ве  на у скло  пу по  ро-
дич  ног те  сти  ра  ња. Ни  во ал  фа-1 ан  ти  трип  си  на у се  ру  му био 
је 0,30–0,66 g/l (про  сеч  но 0,37±0,12 g/l), при че  му код сед  мо-
ро де  це са ZZ фе  но  ти  пом 0,30–0,39 g/l (про  сеч  но 0,33±0,04 
g/l), а код де  ча  ка са FZ фе  но  ти  пом, от  кри  ве  ног по  ро  дич  ним 
скри  нин  гом, 0,66 g/l. У гру  пи бо  ле  сни  ка са хо  ле  ста  зним син-
дро  мом (ни  во GGT у се  ру  му био је у про  се  ку 444,80±203,15 
IU/l; ра  спон 201–676 IU/l), код три де  те  та је утвр  ђе  на бла  га до 
уме  ре  на хе  па  то  ме  га  ли  ја, код јед  ног де  те  та је уочен за  стој у 
лон  ги  ту  ди  нал  ном ра  сту (<П3; -10,50%), док је код дво  је де  це 
за  бе  ле  жен ик  те  рус са кон  ју  го  ва  ном хи  пер  би  ли  ру  би  не  ми  јом 
(92 и 109 μmol/l) и про  ду  же  ним пар  ци  јал  ним вре  ме  ном (14,8 
и 17 s). Код све де  це с хо  ле  ста  зним син  дро  мом утвр  ђе  на је и 
хи  пер  тран  са  ми  на  зе  ми  ја с вред  но  сти  ма ALT 80,83±33 IU/l (ра-
спон 37–124 IU/l) и AST 116,67±62,82 IU/l (ра  спон 58–230 IU/l).
За  кљу  чак Хо  ле  ста  зни син  дром је основ  на ма  ни  фе  ста  ци  ја 
AATD у пр  вим ме  се  ци  ма по ро  ђе  њу де  те  та, док те  сти  ра  ње 
бра  ће и се  ста  ра обо  ле  лих омо  гу  ћа  ва ра  но от  кри  ва  ње и од-
го  ва  ра  ју  ће ле  че  ње суп  кли  нич  ких об  ли  ка бо  ле  сти.
Кључ  не ре  чи: де  фи  цит ал  фа-1 ан  ти  трип  си  на; одој  че; кли-
нич  ке ма  ни  фе  ста  ци  је
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